Project Grant R21DK138178
Award Date
9/1/24
Completion Date
4/30/25
Dollars Obligated
$419K
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30303, USA
Similar Awards
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,428,186.00 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research on the role of CYP4F enzymes in regulating N-acyl amino acid signaling in humans. The project aims to biochemically characterize N-acyl amino acids as substrates and inhibitors of CYP4F...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
This federal Project Grant award of $706,199 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to uncover the mechanisms of NAD depletion in obesity-induced pancreatic beta cell dysfunction and test strategies to restore beta cell mass and function in type 2 diabetes models. The award aims to define changes in NAD biosynthesis and degradation pathways...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is supporting the development of novel therapeutics for obesity and type 2 diabetes. The $1,021,719 grant, awarded to Emmyon, Inc., will fund preclinical studies to advance the development of a proprietary small molecule compound (EMMY1-25) that promotes weight loss without muscle loss and...
This federal Project Grant award of $1,600,000 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research at Beth Israel Deaconess Medical Center, Inc. (BIDMC) to develop a computational pharmacology approach for coordinating the regulation of multiple neuron types related to energy balance and satiety. The research aims to identify combinations of 2-10 ligands...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $199,999 to the University of Florida to develop innovative artificial intelligence (AI)-based methods to support the discovery of potent, orally available small-molecule heparanase inhibitors. The goal is to evaluate these novel heparanase inhibitors in murine models as a...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $659,199 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Pittsburgh. The grant, awarded on February 25, 2025, supports research to investigate a novel pathway by which hepatocyte-derived growth differentiation factor 15 (GDF15) can improve obesity-associated insulin resistance independent of changes in body weight and the GDF15...
This $830,500 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research by Georgetown University to investigate the role of glycosphingolipids in kidney disease associated with diabetes and obesity. The research aims to determine if inhibiting glucosylceramide synthesis can prevent kidney disease progression, improve mitochondrial function, and reduce...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $176,500.00 to the University of Washington to investigate the links between hypothalamic microglia activation and perineuronal net (PNN) loss in the arcuate nucleus, and how these changes contribute to the pathogenesis of diet-induced obesity and glucose regulation. The...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is dedicated to the development and optimization of non-peptide ligands designed to activate insulin receptors. The $772,383 research project aims to transform approaches to glycemic control in the management of diabetes by uncovering a new generation of receptor modulators that could...